Clinical Trial Update: Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of palbociclib in combination with gedatolisib in patients with advanced solid tumors, including lung squamous cell carcinoma, pancreatic cancer, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Lung Squamous Cell Carcinoma
• Pancreatic Cancer

Drugs mentioned

• Gedatolisib (gedatolisib)
• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Lung Cancer Squamous Cell, Solid Tumors | Phase 1 | Status: SUSPENDED